Published in Medical Letter on the CDC and FDA, February 5th, 2006
The allowance of the investigational new drug application (IND) by the U.S. Food and Drug Administration (FDA) triggers a $5 million milestone payment from AstraZeneca to Avanir, the first designated milestone under the terms of the research collaboration and license agreement entered into in July 2005.
"We are pleased that we successfully submitted the U.S. IND for AZD2479 in a timely way. The FDA's allowance of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.